InvestSMART

Racura Oncology Ltd (ASX: RAC) - Share Price

Current share price for RAC : $2.110 0.145 (7.38%)+

Racura Oncology (RAC), an ASX-listed company, is a Phase 3 clinical biopharmaceutical company with a mission to be at the heart of cancer care.

RAC General Information +

ASX Code RAC
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 411
RAC Share Price $2.100
Day High $2.110
Day Low $1.950
Last Close $1.965
RAC Share Price Movement $0.14 ( 6.87% )
Prices as at 13:12, 5 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Racura Oncology Ltd (RAC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Racura Oncology Ltd (RAC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Racura Oncology Ltd (RAC) price-sensitive announcements

RAC - First HARNESS-1 Patient Safely Treated with RC220
Racura Oncology Ltd has announced the successful treatment of the first patient in its HAR
Racura Oncology Ltd (RAC)
29 Jul 2026 | 9:04 AM
RAC - June 2026 Quarterly Activities Report and Appendix 4C
Racura Oncology Ltd reported significant clinical and corporate advancements in its June 2
Racura Oncology Ltd (RAC)
28 Jul 2026 | 9:12 AM
RAC - Bellberry Ethics Approval Activates New HARNESS Trial Sites
Racura Oncology Ltd announced the Bellberry Human Research Ethics Committee (HREC) approva
Racura Oncology Ltd (RAC)
3 Jul 2026 | 8:46 AM
RAC - Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
Racura Oncology Ltd has announced the treatment of the first patient in the HARNESS-1 Phas
Racura Oncology Ltd (RAC)
25 Jun 2026 | 8:55 AM

Racura Oncology Ltd (RAC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $412 Racure Oncology Techknow Invest Presentation 29 Jul 2026 9:12AM $2.040 $2.100 risen by 2.94%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $412 First HARNESS-1 Patient Safely Treated with RC220 29 Jul 2026 9:04AM $2.040 $2.100 risen by 2.94%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $412 June 2026 Quarterly Activities Report and Appendix 4C 28 Jul 2026 9:12AM $2.070 $2.100 risen by 1.45%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $412 Notification of cessation of securities - RAC 13 Jul 2026 8:57AM $2.190 $2.100 fallen by 4.11%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $412 Racura to Present CPACS Data at GCOS 2026 9 Jul 2026 10:42AM $2.130 $2.100 fallen by 1.41%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $412 Racura Oncology New Zealand Investor Events 6 Jul 2026 12:38PM $2.250 $2.100 fallen by 6.67%

RAC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$4.79 -$2.80 -66.90% 0.00 0.00 0.00% 0.0%
2024A -$13.82 -$8.40 36.10% 0.00 0.00 0.00% 0.0%
2023A -$9.92 -$6.20 -15.60% 0.00 0.00 0.00% 0.0%

RAC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $59,529M 0.1108 -0.1207 0.0167 13.3288 15.1576 14.9080 3.59% 2.93% 3.05%
Clinuvel Pharmaceuticals Limited (CUV) $462M 0.0287 0.0000 0.0000 12.7577 0.0000 0.0000 0.55% 0.00% 0.00%
Mesoblast Limited (MSB) $2,636M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Racura Oncology Ltd (RAC) $382M -0.6690 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,852M -1.3893 0.0000 -0.1429 0.0000 234.4828 273.5632 0.00% 0.00% 0.00%

RAC Directors

Name Position Start Date
Dr Daniel Tillett Chief Executive Officer, Managing Director 1 Sep 2024
Dr Peter (Pete) Smith Executive Director, Executive Chairman 28 Jun 2023
Dr Megan Baldwin Non-Executive Director 1 Jan 2025
Dr Serge Scrofani Non-Executive Director 1 Sep 2024

Racura Oncology Ltd (RAC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
5 Jun 2026 SCROFANI, Serge Buy Indirect Shares 11,285 $2.692 $30,375.290
28 May 2026 TILLETT, Daniel Exercise Options 400,000 $1.250 $500,000.000
28 May 2026 TILLETT, Daniel Buy Direct Shares 400,000 $1.250 $500,000.000

See all changes in directors' interest & trades for Racura Oncology Ltd (RAC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAC Management

Name Position
Peter Webse Company Secretary

RAC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Racura Oncology Ltd (RAC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
17,267,615 (9.94%) Daniel Tillett

RAC Calendar of Events

Date Event
26 February 2027 Report (Interim)
25 August 2026 Report (Annual)
25 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.